Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.

Informe acción SHSE:688076

Capitalización de mercado: CN¥10.6b

Jiangsu Sinopep-Allsino Biopharmaceutical Resultados de beneficios anteriores

Pasado controles de criterios 4/6

Jiangsu Sinopep-Allsino Biopharmaceutical has been growing earnings at an average annual rate of 32.7%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 26.6% per year. Jiangsu Sinopep-Allsino Biopharmaceutical's return on equity is 16.1%, and it has net margins of 26.7%.

Información clave

32.7%

Tasa de crecimiento de los beneficios

24.9%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals 10.9%
Tasa de crecimiento de los ingresos26.6%
Rentabilidad financiera16.1%
Margen neto26.7%
Última actualización de beneficios30 Sep 2024

Actualizaciones de resultados anteriores recientes

Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit

Apr 04
Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit

Recent updates

Should You Be Adding Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) To Your Watchlist Today?

Sep 26
Should You Be Adding Jiangsu Sinopep-Allsino Biopharmaceutical (SHSE:688076) To Your Watchlist Today?

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable

Jun 23
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) Stocks Shoot Up 32% But Its P/E Still Looks Reasonable

Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit

Apr 04
Jiangsu Sinopep-Allsino Biopharmaceutical's (SHSE:688076) Shareholders May Want To Dig Deeper Than Statutory Profit

There's Reason For Concern Over Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Massive 27% Price Jump

Mar 04
There's Reason For Concern Over Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Massive 27% Price Jump

Desglose de ingresos y gastos

Cómo gana y gasta dinero Jiangsu Sinopep-Allsino Biopharmaceutical. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

SHSE:688076 Ingresos, gastos y beneficios (CNY Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Sep 241,576421339212
30 Jun 241,464348324196
31 Mar 241,181208300171
31 Dec 231,034163273125
30 Sep 23979168255105
30 Jun 2378413622076
31 Mar 2372513420777
31 Dec 2265112919369
30 Sep 225769518168
30 Jun 226039917465
31 Mar 226129216361
31 Dec 2164411515263
30 Sep 2164211315162
30 Jun 2166012613966
31 Mar 2168715913666
31 Dec 2056712312261
30 Sep 204819411252
30 Jun 20425749450
31 Mar 20353469345
31 Dec 19372498948
30 Sep 19313407956
30 Jun 19266318347
31 Mar 19298597439
31 Dec 18256447235
30 Sep 18284667129
30 Jun 18286716325
31 Mar 18245465623
31 Dec 17229425418
30 Sep 17156-7637
30 Jun 17104-46794
31 Mar 1726-66750
31 Dec 169-75720
30 Sep 166-53520
30 Jun 163-33310
31 Mar 166-32290
31 Dec 159-30270
31 Dec 140-25190

Ingresos de calidad: 688076 has a high level of non-cash earnings.

Margen de beneficios creciente: 688076's current net profit margins (26.7%) are higher than last year (17.1%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 688076's earnings have grown significantly by 32.7% per year over the past 5 years.

Acelerando crecimiento: 688076's earnings growth over the past year (151.4%) exceeds its 5-year average (32.7% per year).

Beneficios vs. Industria: 688076 earnings growth over the past year (151.4%) exceeded the Pharmaceuticals industry -1.2%.


Rentabilidad financiera

Alta ROE: 688076's Return on Equity (16.1%) is considered low.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado